- Home
- EXP vs IBRX Comparison
EXP vs IBRX Comparison
Compare EXP & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXP | IBRX |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 8.2B |
| IPO Year | 1994 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EXP | IBRX |
|---|---|---|
| Price | $169.38 | $9.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $195.50 | $14.25 |
| AVG Volume (30 Days) | 428.6K | ★ 13.0M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ 38.71 |
| EPS | ★ 3.29 | N/A |
| Revenue | ★ $495,023,000.00 | $113,288,000.00 |
| Revenue This Year | $0.74 | $99.98 |
| Revenue Next Year | $3.12 | $108.29 |
| P/E Ratio | $51.85 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $160.02 | $1.95 |
| 52 Week High | $245.53 | $12.43 |
Technical Indicators
Market Signals| Indicator | EXP | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.62 | 51.55 |
| Support Level | N/A | $6.68 |
| Resistance Level | $218.97 | $9.54 |
| Average True Range (ATR) | 4.02 | 0.63 |
| MACD | 0.77 | -0.02 |
| Stochastic Oscillator | 54.33 | 41.60 |
Price Performance
Historical ComparisonAbout EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.